PMID- 19420756
OWN - NLM
STAT- MEDLINE
DCOM- 20090709
LR  - 20190720
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 32
IP  - 5
DP  - 2009 May
TI  - Silibinin attenuates mast cell-mediated anaphylaxis-like reactions.
PG  - 868-75
AB  - Silibinin is known to have hepatoprotective, anti-carcinogenic and 
      anti-inflammatory effects. However, roles of silibinin in the immediate-type 
      allergic reactions (anaphylaxis) have not fully been investigated. In the present 
      study, we have demonstrated that silibinin attenuated mast cell-mediated 
      anaphylaxis-like reactions involved in allergic diseases. Oral administration of 
      silibinin inhibited compound 48/80-induced passive cutaneous anaphylaxis-like 
      reaction in mice. Silibinin also attenuated anti-dinitrophenyl (DNP) 
      immunoglobulin (Ig) E-mediated passive systemic and cutaneous anaphylaxis. 
      Silibinin had no cytotoxicity on rat peritoneal mast cells (RPMC). Silibinin 
      dose-dependently reduced histamine release from RPMC activated by compound 48/80 
      or anti-DNP IgE. Moreover, silibinin inhibited the secretion of pro-inflammatory 
      cytokines, such as tumor necrosis factor-alpha and interleukin-6 in RPMC. 
      Pretreatment of silibinin suppressed the antigen-stimulated calcium uptake and 
      activation of nuclear factor-kappa B (NF-kappaB) in RPMC. Furthermore, silibinin 
      increased the intracellular cAMP level. Increased cAMP, decreased calcium uptake 
      and suppressed NF-kappaB activity might be involved in the inhibitory effect of 
      silibinin on the secretory response. Our findings provide possibility that 
      silibinin may serve as an effective therapeutic agent for allergic diseases.
FAU - Choi, Yun Ho
AU  - Choi YH
AD  - Department of Anatomy, Chonbuk National University Medical School, Jeonbuk, 
      Republic of Korea.
FAU - Yan, Guang Hai
AU  - Yan GH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Interleukin-6)
RN  - 0 (NF-kappa B)
RN  - 0 (Silymarin)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 4RKY41TBTF (Silybin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Anaphylaxis/immunology/metabolism/*prevention & control
MH  - Animals
MH  - Anti-Allergic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Calcium/metabolism
MH  - Cell Nucleus/drug effects/metabolism
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Cytosol/drug effects/metabolism
MH  - Disease Models, Animal
MH  - Histamine Release/*drug effects
MH  - Interleukin-6/immunology/metabolism
MH  - Male
MH  - Mast Cells/*drug effects/metabolism
MH  - Mice
MH  - Mice, Inbred ICR
MH  - NF-kappa B/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Silybin
MH  - Silymarin/administration & dosage/pharmacology/therapeutic use
MH  - Tumor Necrosis Factor-alpha/immunology/metabolism
EDAT- 2009/05/08 09:00
MHDA- 2009/07/10 09:00
CRDT- 2009/05/08 09:00
PHST- 2009/05/08 09:00 [entrez]
PHST- 2009/05/08 09:00 [pubmed]
PHST- 2009/07/10 09:00 [medline]
AID - JST.JSTAGE/bpb/32.868 [pii]
AID - 10.1248/bpb.32.868 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2009 May;32(5):868-75. doi: 10.1248/bpb.32.868.